179 related articles for article (PubMed ID: 9158080)
21. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
[TBL] [Abstract][Full Text] [Related]
22. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.
Archer DF; Dorin M; Lewis V; Schneider DL; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1080-7. PubMed ID: 11384630
[TBL] [Abstract][Full Text] [Related]
23. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
24. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
25. Hormone replacement therapy and lipid-lipoprotein concentrations.
Gökmen O; Yapar Eyi EG
Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):31-41. PubMed ID: 10428319
[TBL] [Abstract][Full Text] [Related]
26. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
[TBL] [Abstract][Full Text] [Related]
27. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Utian WH; Shoupe D; Bachmann G; Pinkerton JV; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1065-79. PubMed ID: 11384629
[TBL] [Abstract][Full Text] [Related]
28. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial.
AinMelk Y
Fertil Steril; 1996 Dec; 66(6):962-8. PubMed ID: 8941062
[TBL] [Abstract][Full Text] [Related]
30. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
31. Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail.
Zhu SY; Deng Y; Wang YF; Xue W; Ma X; Sun A
Gynecol Endocrinol; 2019 Feb; 35(2):165-169. PubMed ID: 30449208
[TBL] [Abstract][Full Text] [Related]
32. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial.
Recker RR; Davies KM; Dowd RM; Heaney RP
Ann Intern Med; 1999 Jun; 130(11):897-904. PubMed ID: 10375338
[TBL] [Abstract][Full Text] [Related]
33. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
[TBL] [Abstract][Full Text] [Related]
34. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism.
Lobo RA; Bush T; Carr BR; Pickar JH
Fertil Steril; 2001 Jul; 76(1):13-24. PubMed ID: 11438314
[TBL] [Abstract][Full Text] [Related]
35. Differential time-related effects of conjugated equine estrogen on bone metabolism in oophorectomized women.
Nozaki M; Inoue Y; Hashimoto K; Ogata R; Nakano H
Int J Gynaecol Obstet; 1998 Jan; 60(1):41-6. PubMed ID: 9506413
[TBL] [Abstract][Full Text] [Related]
36. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
[TBL] [Abstract][Full Text] [Related]
37. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
38. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
[TBL] [Abstract][Full Text] [Related]
39. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women.
Cummings JA; Brizendine L
Menopause; 2002; 9(4):253-63. PubMed ID: 12082361
[TBL] [Abstract][Full Text] [Related]
40. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
